All Stories

TegMine, with ex-Stemcentrx scientists at the helm, bags tech from OBI to help fuel ADC ambitions

TegMine Therapeutics has secured certain rights to OBI Pharma’s antibody-drug conjugate technology, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates.

Jun 6, 2025 - 16:15
 0
TegMine, with ex-Stemcentrx scientists at the helm, bags tech from OBI to help fuel ADC ambitions
TegMine Therapeutics has secured certain rights to OBI Pharma’s antibody-drug conjugate technology, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates.
Read More

Tags:

Previous Article

Regulatory tracker: AZ's fixed-duration Calquence regimen picks up EU nod in fir...

Next Article

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

Related Posts

Fierce Biotech Fundraising Tracker '25: SpyGlass secures $75M series D; Vima launches with $60M

Fierce Biotech Fundraising Tracker '25: SpyGlass secure...

Jun 2, 2025  0

Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential

Blueprint changes up $1.67B VantAI pact again, zeroing ...

May 20, 2025  0

Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M

Eli Lilly enlists Camurus to help unlock long-acting ob...

Jun 3, 2025  0